First head-to-head trial pits psychedelic therapy against antidepressant
“The results, recently published in the New England Journal of Medicine, are decidedly mixed with the primary depression measure revealing no significant difference between the two treatments, but a number of secondary measures notably favoring psilocybin.” | learn more